Aethlon Medical Prices 5.6M Shares and Warrants at $0.7101 in $4M ATM Offering
AEMD•Aethlon Medical is offering 5,633,009 shares (or pre-funded warrants) and equal number of warrants in an at-the-market offering priced at $0.7101 per unit to raise about $4.0 million in gross proceeds. Net proceeds will fund research and development, ongoing clinical trials, capital expenditures, working capital and potential in-license or acquisitions.
1. Offering Details
Aethlon Medical has priced a follow-on at-the-market offering of 5,633,009 shares of common stock, or pre-funded warrants, and 5,633,009 detachable warrants at $0.7101 per unit, targeting approximately $4.0 million in gross proceeds. The offering is slated to close on or about July 7, 2026, subject to customary closing conditions.
2. Warrant Terms
The detachable warrants carry an exercise price of $0.7101 per share, will become exercisable upon receipt of stockholder approval, and will expire five years after that approval date. The shares (or pre-funded warrants) and warrants are immediately separable and will be issued separately.
3. Use of Proceeds
Net proceeds are earmarked for research and development, clinical trial expenses, capital expenditures and working capital, with potential allocation toward in-licensing, acquisitions or investments in complementary technologies or assets. This infusion aims to support expansion of the Hemopurifier® program and broader corporate initiatives.
4. Company Background
Aethlon Medical develops the Hemopurifier®, a clinical-stage immunotherapeutic device designated as an FDA Breakthrough Device for treating advanced or metastatic cancer and life-threatening viral infections. The Hemopurifier® has demonstrated removal of harmful viruses and extracellular vesicles in human and pre-clinical studies using proprietary lectin-based technology.
